Assays to predict drug permeation across the blood-brain barrier, and distribution to brain
- PMID: 18991587
- DOI: 10.2174/138920008786485182
Assays to predict drug permeation across the blood-brain barrier, and distribution to brain
Abstract
Drug discovery programmes to target or avoid the brain need to take into account the properties of the blood-brain barrier (BBB). The importance to CNS PK of the free drug concentration in brain is increasingly recognised, and assays for drug discovery programmes are being adjusted accordingly. In vitro models of the BBB continue to play an important role in this process. Good cell-based models using brain endothelium have been developed and validated for mechanistic studies, and some are suitable for medium to high throughput permeability screening and toxicology. Brain homogenate and brain slice methods allow estimation of drug partition into brain. In combination with in silico and in vivo models, the portfolio of methods establishing and predicting CNS drug PK is now very powerful, allowing much more accurate iterative feedback to chemists to optimise compound profiles through the drug discovery and development programme. The advantage of using models based on real BBB cellular anatomy and physiology is that they have the power to reveal and incorporate previously undiscovered properties, such as new transporters, metabolic enzymes and modulation, to form the basis for models mimicking neurological disorders as well as normal function, and to allow physiologically-based pharmacokinetic (PBPK) extrapolation from animal models to humans.
Similar articles
-
Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo.Curr Drug Metab. 2002 Dec;3(6):647-57. doi: 10.2174/1389200023337063. Curr Drug Metab. 2002. PMID: 12369891 Review.
-
Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration.Eur J Pharm Biopharm. 2018 Jun;127:453-461. doi: 10.1016/j.ejpb.2018.03.007. Epub 2018 Mar 28. Eur J Pharm Biopharm. 2018. PMID: 29602020
-
Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.Chem Biodivers. 2009 Nov;6(11):2030-49. doi: 10.1002/cbdv.200900103. Chem Biodivers. 2009. PMID: 19937839 Review.
-
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.AAPS J. 2013 Oct;15(4):913-32. doi: 10.1208/s12248-013-9496-0. Epub 2013 Jun 20. AAPS J. 2013. PMID: 23784110 Free PMC article. Review.
-
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition.AAPS J. 2022 Jan 13;24(1):28. doi: 10.1208/s12248-021-00675-w. AAPS J. 2022. PMID: 35028763 Free PMC article. Review.
Cited by
-
Bypassing the blood-brian barrier using established skull base reconstruction techniques.World J Otorhinolaryngol Head Neck Surg. 2015 Oct 23;1(1):11-16. doi: 10.1016/j.wjorl.2015.09.001. eCollection 2015 Sep. World J Otorhinolaryngol Head Neck Surg. 2015. PMID: 29204535 Free PMC article. Review.
-
Characterization of a novel brain barrier ex vivo insect-based P-glycoprotein screening model.Pharmacol Res Perspect. 2014 Aug;2(4):e00050. doi: 10.1002/prp2.50. Epub 2014 Jun 9. Pharmacol Res Perspect. 2014. PMID: 25505597 Free PMC article.
-
A detailed method for preparation of a functional and flexible blood-brain barrier model using porcine brain endothelial cells.Brain Res. 2013 Jul 12;1521:16-30. doi: 10.1016/j.brainres.2013.04.006. Epub 2013 Apr 17. Brain Res. 2013. PMID: 23603406 Free PMC article.
-
The development and function of the brain barriers - an overlooked consideration for chemical toxicity.Front Toxicol. 2022 Oct 18;4:1000212. doi: 10.3389/ftox.2022.1000212. eCollection 2022. Front Toxicol. 2022. PMID: 36329715 Free PMC article. Review.
-
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.Clin Pharmacokinet. 2011 Aug;50(8):483-91. doi: 10.2165/11592400-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21740072
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical